Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06643780

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis

The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

The Chinese University of Hong Kong

Hong Kong, China

Location status: Recruiting

Location contact

Ronald Man Yeung Wong

CONTACT

[email protected]

852 3505 1654

About this study

Aims:

  • To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
  • To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elderly males or females aged 65 years or older
  • diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
  • Willing and able to comply with study protocol including follow-up evaluations.

Exclusion criteria

  • history of recent fracture i.e., within 3 months
  • history of prior anti-osteoporotic drug
  • disease or medication affecting bone or muscle metabolism
  • Chairbound or bedbound
  • Unable to agree for consent
  • contraindication to drug i.e., Denosumab or Zoledronic Acid
  • Underlying malignancy or disease known to cause cachexia
  • severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
  • moderate to severe liver failure (Child-Pugh Class B or C).

Treatment and study plan

Denosumab

Drug

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

zolendronic acid

Drug

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

Primary outcomes

  1. 6-metre walk

    Time frame: From enrollment to the end of treatment at 52 weeks

    The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as <1.0m/s.

  2. 5-time chair stand test

    Time frame: From enrollment to the end of treatment at 8 weeks

    The time to rise from a chair 5 times is recorded. The cut-off for is taken at >=12 seconds.

  3. Appendicular skeletal muscle mass (ASM)

    Time frame: From enrollment to the end of treatment at 52 weeks

    Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is < 7 kg/m2 for men and 5.4 kg/m2 for women.

  4. Handgrip strength

    Time frame: From enrollment to the end of treatment at 52 weeks

    Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is < 28kg, and female is <18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction

  5. Quadriceps muscle strength

    Time frame: From enrollment to the end of treatment at 52 weeks

    Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation

  6. Balancing ability

    Time frame: From enrollment to the end of treatment at 52 weeks

    The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%).

  7. Balancing ability

    Time frame: From enrollment to the end of treatment at 52 weeks

    The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s)

  8. Balancing ability

    Time frame: From enrollment to the end of treatment at 52 weeks

    The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%)

  9. Balancing ability

    Time frame: From enrollment to the end of treatment at 52 weeks

    The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%)

  10. Balancing ability

    Time frame: From enrollment to the end of treatment at 52 weeks

    The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s)

Secondary outcomes

  1. Falls

    Time frame: From enrollment to the end of treatment at 52 weeks

    To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year

  2. Fracture

    Time frame: From enrollment to the end of treatment at 52 weeks

    Assess occurrence of a fracture within a year of study period.

  3. Quality of life Short Form-36 (SF-36)

    Time frame: From enrollment to the end of treatment at 52 weeks

    The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life.

  4. Physical activity scale for elderly (PASE)

    Time frame: From enrollment to the end of treatment at 52 weeks

    It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity

  5. Food frequency questionnaire

    Time frame: From enrollment to the end of treatment at 52 weeks

    Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong.

  6. Hospital admissions

    Time frame: From enrollment to the end of treatment at 52 weeks

    Number and cause of emergency hospital admission within 1 year of study period are documented.

  7. Mortality

    Time frame: From enrollment to the end of treatment at 52 weeks

    Mortality within 1-year of study period is documented.

Study contacts

Contact information is provided by the study sponsor or research team.

Ronald Man Yeung Wong

CONTACT

[email protected]

852 3505 1654

Sponsors and collaborators

Lead sponsor

Prince of Wales Hospital, Shatin, Hong Kong

Other

Collaborators

  • Chinese University of Hong Kong

Registry information

Official study title

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: a Randomized, Double-blind, Double-dummy, Active-Controlled Trial

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 16, 2024
Registry last updated
Oct 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.